Vivanza Biosciences Limited has closed its trading window for dealing in securities, effective from Thursday, October 1, 2026. The closure will remain in force until the expiry of 48 hours after the declaration of the company's unaudited financial results for the quarter ending September 30, 2026.

This action is taken pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The restriction applies to all Designated Persons and their immediate relatives as defined under the company's code of conduct.

Restrictions on Trading

All Designated Persons, including dependents and immediate relatives, along with connected persons, are advised not to enter into any transaction involving the securities of the company during the closure period. This measure ensures compliance with insider trading norms while sensitive financial information is being finalized.

The notice was signed by Jayendra Amichand Mehta, Managing Director of Vivanza Biosciences. The communication was addressed to the Department of Corporate Services at BSE Limited on September 28, 2026.

Vivanza Biosciences shareholders approved all nine resolutions at the company’s 44th Annual General Meeting held on September 11, 2026, with voting results showing near-unanimous support for key governance and financial authority measures.

The meeting was conducted via video conferencing in compliance with Ministry of Corporate Affairs circulars. Remote e-voting was open from September 8 to September 10, 2026, through National Securities Depository Limited (NSDL). No votes were cast during the live AGM session, as all participation occurred via remote e-voting.

Voting Results by Resolution

The scrutinizer’s report, submitted by Chintan K. Patel, detailed the vote counts for each resolution. All proposals passed comfortably, with several receiving 100% of valid votes cast.

Key Resolutions Approved

Shareholders voted on several ordinary and special business items. The primary focus included governance updates and financial authority expansions.

• Financial Statements: The adoption of FY26 audited standalone and consolidated financial statements received unanimous support (100%).
• Director Appointments: Mr. Jayendra Mehta was re-appointed as Director with 99.99% support. Mr. H.A. Parikh was regularized as a Non-Executive Non-Independent Director with 100% support.
• Borrowing & Investments: Shareholders approved an increase in borrowing limits under Section 180(1)(C) with 99.99% support. Authority for investments, loans, and guarantees under Section 186 also passed with 99.99% support.
• Governance Documents: New Memorandum and Articles of Association were adopted with 100% approval.

Management Commentary

Mr. Jainil Bhatt, Chief Financial Officer, apprised members of the company’s financial performance and future prospects. No questions or queries were raised by shareholders during the session.

The Chairman and Managing Director, Mr. Mehta J.A., presided over the meeting. Other attendees included Independent Directors Mr. Hitesh Rijwani and Ms. Reena Kumari, along with Statutory Auditor Mr. Shivam Soni and Secretarial Auditor Mr. Chintan Patel.

Voting Process and Corrigendum

Mr. Chintan K. Patel served as the Scrutinizer for the voting process. The combined results were disseminated to stock exchanges within 48 hours of the meeting's conclusion.

The company issued a corrigendum on September 12, 2026, clarifying that the e-voting service provider was National Securities Depository Limited (NSDL), not Central Depository Services (India) Limited (CDSL) as erroneously stated in the initial report. The voting percentages and resolution outcomes remain unchanged.